Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-in Capital	Additional Paid-in Capital Cumulative Effect, Period of Adoption, Adjustment	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Loss
Beginning Balance (in shares) at Dec. 31, 2020			34,481
Beginning Balance at Dec. 31, 2020	$ 1,400,181		$ 345	$ 0		$ 1,506,271		$ (106,435)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	64,496					64,496
Other comprehensive income (loss)
Cumulative translation adjustment	(5,242)							(5,242)
Issuance of common stock in connection with:
Exercise of options (in shares)			12
Exercise of options	434			434
Restricted share grants (in shares)			157
Restricted share grants	(7,231)		$ 1	(7,232)
Stock units issued under incentive compensation plan	2,603			2,603
Purchase and retirement of common stock (in shares)			(422)
Purchase and retirement of common stock	(46,133)		$ (4)	(3,047)		(43,082)
Share-based compensation	7,242			7,242
Ending Balance (in shares) at Mar. 31, 2021			34,228
Ending Balance at Mar. 31, 2021	$ 1,416,350		$ 342	0		1,527,685		(111,677)
Beginning Balance (in shares) at Dec. 31, 2021	34,333		34,333
Beginning Balance at Dec. 31, 2021	$ 1,583,321	$ (12,053)	$ 343	13,662	$ (34,131)	1,698,156	$ 22,078	(128,840)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	59,321					59,321
Other comprehensive income (loss)
Cumulative translation adjustment	(6,191)							(6,191)
Issuance of common stock in connection with:
Exercise of options (in shares)			26
Exercise of options	923			923
Restricted share grants (in shares)			134
Restricted share grants	(7,834)		$ 2	(7,836)
Stock units issued under incentive compensation plan	1,664			1,664
Purchase and retirement of common stock (in shares)			(22)
Purchase and retirement of common stock	(3,098)			(3,098)
Conversion of convertible senior notes due 2023	(2)			(2)
Share-based compensation	5,967			5,967
Reclassification of negative additional paid-in capital	$ 0			22,851		(22,851)
Ending Balance (in shares) at Mar. 31, 2022	34,471		34,471
Ending Balance at Mar. 31, 2022	$ 1,622,018		$ 345	$ 0		$ 1,756,704		$ (135,031)